Diabetes.
The causes of accelerated atherogenesis in diabetes are unclear but the consequences in terms of cardiovascular morbidity and mortality are profound. Thus diabetes not only increases the risk of coronary heart disease but also increases the case fatality rate, ensuring that the majority of patients die of cardiovascular causes, often before the age of 50 years. The problem is compounded by autonomic neuropathy which alters the perception of cardiac pain, attenuating symptoms which are often atypical or absent. This may delay presentation or lead to inappropriate triage decisions such that access to defibrillators and specific treatment is denied. Central to the cardiovascular management of diabetes is vigorous risk factor modification although clear evidence that this leads to extra protection against coronary heart disease beyond that achieved in non-diabetic individuals has not been forthcoming. In other respects too, the management of diabetic patients with heart disease is underpinned by the same evidence-base as applies to non-diabetic patients, and it is noteworthy that 15-20% of the patients in most of the landmark clinical trials have been diabetic. Recently, however, trials such as the United Kingdom Prospective Diabetes Study (UKPDS), the Heart Outcomes Prevention Evaluation (HOPE) study, and the Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study have identified novel strategies for reducing cardiovascular risk in diabetes. These trials have already had a major impact on cardiological practice, emphasising the prime importance of blood pressure control and converting enzyme inhibition for reducing cardiovascular risk in diabetes as well as the value of insulin therapy for reducing mortality in diabetic myocardial infarction. Additional trials, already in progress, are expected to refine further the cardiovascular management of patients with diabetes in order to provide an effective challenge for a problem that shows no signs of going away.
Timmis
A D
AD
Department of Cardiology, London Chest Hospital, London, UK.
D000787:Angina Pectoris / Q000209:etiology / Q000601:surgery; D001161:Arteriosclerosis / Q000209:etiology / Q000378:metabolism / Q000628:therapy; D001786:Blood Glucose / Q000378:metabolism; D003327:Coronary Disease / Q000209:etiology* / Q000378:metabolism / Q000628:therapy; D016757:Death, Sudden, Cardiac / Q000209:etiology; D003925:Diabetic Angiopathies / Q000209:etiology* / Q000378:metabolism / Q000628:therapy; D005260:Female; D006333:Heart Failure / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007328:Insulin / Q000378:metabolism; D008055:Lipids / Q000097:blood; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy / Q000209:etiology; D009204:Myocardial Revascularization; D012306:Risk; D012307:Risk Factors; D015912:Thrombolytic Therapy
D001786:Blood Glucose; D007328:Insulin; D008055:Lipids